Syros Pharmaceuticals Inc’s filing revealed that its President & CEO Chee Conley acquired Company’s shares for reported $85420.0 on Sep 11 ’24. In the deal valued at $1.71 per share,50,000 shares were bought. As a result of this transaction, Chee Conley now holds 122,504 shares worth roughly $0.28 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Haas Jason bought 45,344 shares, generating $76,006 in total proceeds. Upon buying the shares at $1.68, the Chief Financial Officer now owns 124,552 shares.
Before that, Chee Conley bought 50,000 shares. Syros Pharmaceuticals Inc shares valued at $75,260 were divested by the President & CEO at a price of $1.51 per share. As a result of the transaction, Chee Conley now holds 72,504 shares, worth roughly $0.16 million.
H.C. Wainwright upgraded its Syros Pharmaceuticals Inc [SYRS] rating to a Buy from a a Neutral in a research note published on November 04, 2020; the price target was increased to $15 from $11. A number of analysts have revised their coverage, including Alliance Global Partners’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Wedbush also remained covering SYRS and has decreased its forecast on January 17, 2020 with a “Neutral” recommendation from previously “an Outperform” rating.
Price Performance Review of SYRS
On Friday, Syros Pharmaceuticals Inc [NASDAQ:SYRS] saw its stock fall -10.12% to $2.27. Over the last five days, the stock has gained 13.25%. Syros Pharmaceuticals Inc shares have fallen nearly -70.92% since the year began. Nevertheless, the stocks have fallen -5.23% over the past one year. While a 52-week high of $8.17 was reached on 01/02/24, a 52-week low of $1.43 was recorded on 09/10/24. SMA at 50 days reached $1.92, while 200 days put it at $4.73.
Levels Of Support And Resistance For SYRS Stock
The 24-hour chart illustrates a support level at 2.11, which if violated will result in even more drops to 1.95. On the upside, there is a resistance level at 2.37. A further resistance level may holdings at 2.48. The Relative Strength Index (RSI) on the 14-day chart is 53.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.16%. Stochastics %K at 64.39% indicates the stock is a holding.
How much short interest is there in Syros Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syros Pharmaceuticals Inc stocks on 2024-10-15, dropping by -0.15 million shares to a total of 0.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 1.1 million shares. There was a decline of -15.67%, which implies that there is a negative sentiment for the stock.
